NEW YORK, July 15, 2015 /PRNewswire/ -- Attorney
Advertising -- Bronstein, Gewirtz & Grossman, LLC is
investigating potential claims against the Board of Directors of
Receptos, Inc. ("Receptos" or the "Company") (NasdaqGS: RCPT)
related to the proposed acquisition of the Company by Celgene
Corporation. The transaction is valued at around $7.3 Billion or $232 per share.
This investigation concerns whether the Board of Directors of
Receptos breached their fiduciary duties to stockholders by failing
to adequately shop the Company before agreeing to enter into the
proposed transaction, and whether the Company has disclosed all
material information to shareholders about the transaction.
If you own Receptos common stock and wish to obtain additional
information, please contact either Peretz
Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz &
Grossman, LLC at 212-697-6484 or via email info@bgandg.com. Those
who inquire by e-mail are encouraged to include their mailing
address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation
boutique. Our primary expertise is the aggressive pursuit of
litigation claims on behalf of our clients. In addition to
representing institutions and other investor plaintiffs in class
action security litigation, the firm's expertise includes general
corporate and commercial litigation, as well as securities
arbitration. Attorney advertising. Prior results do not
guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/investor-alert-bronstein-gewirtz--grossman-llc-announces-investigation-of-receptos-inc-concerning-its-proposed-sale-to-celgene-corporation-300113411.html
SOURCE Bronstein, Gewirtz & Grossman, LLC